Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Scott Eliasof"'
Autor:
Robert S. Kerbel, Carolyn Krasner, Ping Xu, Christian G. Peters, Ursula A. Matulonis, Shan Man, Christina R. Lee, Douglas Lazarus, Edward G. Garmey, Scott Eliasof, Michael J. Birrer, Elizabeth Pham
Purpose: Increased tumor hypoxia and hence elevated hypoxia-inducible factor-1α (HIF1α) is thought to limit the efficacy of vascular endothelial growth factor (VEGF) pathway–targeting drugs by upregulating adaptive resistance genes. One strategy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2703f4aeca8077a90c697a527a910ca9
https://doi.org/10.1158/1078-0432.c.6523931.v1
https://doi.org/10.1158/1078-0432.c.6523931.v1
Autor:
Robert S. Kerbel, F. Stuart Foster, Scott Eliasof, Douglas Lazarus, Annabelle Chow, Ellen Rohde, Lata Jayaraman, Shan Man, Ping Xu, Donna Brown, Christina R. Lee, Christian G. Peters, Melissa Yin, Elizabeth Pham
VEGF pathway–targeting antiangiogenic drugs, such as bevacizumab, when combined with chemotherapy have changed clinical practice for the treatment of a broad spectrum of human cancers. However, adaptive resistance often develops, and one major mech
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8326e19cc9586d17287f85a14d80afba
https://doi.org/10.1158/0008-5472.c.6508295.v1
https://doi.org/10.1158/0008-5472.c.6508295.v1
Autor:
Robert S. Kerbel, F. Stuart Foster, Scott Eliasof, Douglas Lazarus, Annabelle Chow, Ellen Rohde, Lata Jayaraman, Shan Man, Ping Xu, Donna Brown, Christina R. Lee, Christian G. Peters, Melissa Yin, Elizabeth Pham
Description of additional methods and procedures used in the study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c81d37323519ca66c2f3c1b5eb841b0
https://doi.org/10.1158/0008-5472.22411781
https://doi.org/10.1158/0008-5472.22411781
Autor:
Robert S. Kerbel, F. Stuart Foster, Scott Eliasof, Douglas Lazarus, Annabelle Chow, Ellen Rohde, Lata Jayaraman, Shan Man, Ping Xu, Donna Brown, Christina R. Lee, Christian G. Peters, Melissa Yin, Elizabeth Pham
Bioluminescence imaging of mice bearing primary LM2-4 tumors (S1); Assessment of MVD, HIF-1α, and tumoral drug accumulation in PDX primary tumors (S2); Immunohistochemistry staining for CD31, CAIX, caspase 3, Ki67, and HIF-1α, as well as in vitro V
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::173d464fc496bfd3274a5bef741dced1
https://doi.org/10.1158/0008-5472.22411784
https://doi.org/10.1158/0008-5472.22411784
Autor:
Robert S. Kerbel, Carolyn Krasner, Ping Xu, Christian G. Peters, Ursula A. Matulonis, Shan Man, Christina R. Lee, Douglas Lazarus, Edward G. Garmey, Scott Eliasof, Michael J. Birrer, Elizabeth Pham
Supplemental Figures 1-5 and Methods. This file describes the change in HIF-1α, HIF-2α and downstream markers (Fig. S1), anti-tumor efficacy and change in HIF-1α when combining CRLX101 with Aflibercept (Fig. S2) or Pazopanib (Fig. S3), dose-depend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a317bc2735a439ca3b366162b704fd29
https://doi.org/10.1158/1078-0432.22458377
https://doi.org/10.1158/1078-0432.22458377
Autor:
Andrew Z. Wang, Scott Eliasof, Joel E. Tepper, Edward G. Garmey, Lata Jayaraman, Pauline Wu, Christian G. Peters, Kyle C. Roche, Joseph M. Caster, Henry P. Foote, Minh Nguyen, Xi Tian
There is a linear relationship between the number of HT-29-Luc2 cells and the luminescence intensity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48192726a39d9b6700ab1ada4d46fa9d
https://doi.org/10.1158/0008-5472.22408665
https://doi.org/10.1158/0008-5472.22408665
Autor:
Andrew Z. Wang, Scott Eliasof, Joel E. Tepper, Edward G. Garmey, Lata Jayaraman, Pauline Wu, Christian G. Peters, Kyle C. Roche, Joseph M. Caster, Henry P. Foote, Minh Nguyen, Xi Tian
Novel agents are needed to improve chemoradiotherapy for locally advanced rectal cancer. In this study, we assessed the ability of CRLX101, an investigational nanoparticle–drug conjugate containing the payload camptothecin (CPT), to improve therape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::970f87f91008f0326f1578a1cb55c305
https://doi.org/10.1158/0008-5472.c.6507588.v1
https://doi.org/10.1158/0008-5472.c.6507588.v1
Autor:
Andrew Z. Wang, Scott Eliasof, Joel E. Tepper, Edward G. Garmey, Lata Jayaraman, Pauline Wu, Christian G. Peters, Kyle C. Roche, Joseph M. Caster, Henry P. Foote, Minh Nguyen, Xi Tian
Evaluation of skin toxicity following drug with radiation (XRT) treatment. (A) Representative images and (B) quantification of skin toxicities observed in animals 49 days following treatment with PBS (Control), CPT, or CRLX101 with radiation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::75907a823d2e457a0347b426cbee2c62
https://doi.org/10.1158/0008-5472.22408662
https://doi.org/10.1158/0008-5472.22408662
Autor:
Geeti Gangal, Sonke Svenson, Chester A. Metcalf, Pochi Shum, Snehlata Tripathi, Jungyeon Hwang, Stephanie Harlfinger, Beata Sweryda-Krawiec, Roy I. Case, Douglas Lazarus, Derek van der Poll, Sujan Kabir, Donna Brown, Ellen Rohde, Chi-Hse Teng, Roderic O. Cole, Scott Eliasof
Publikováno v:
Journal of Medicinal Chemistry. 62:9541-9559
Novel nanoparticle-drug conjugates (NDCs) containing diverse, clinically relevant anticancer drug payloads (docetaxel, cabazitaxel, and gemcitabine) were successfully generated and tested in drug discovery studies. The NDCs utilized structurally vari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27195bb3a1196c25d218ec36152dd0c0
https://doi.org/10.1021/acs.jmedchem.9b00892
https://doi.org/10.1021/acs.jmedchem.9b00892
Autor:
Mark E. Davis, Eloise Luevanos, Joseph Chao, Paul Frankel, Yun Yen, Devin T. Wiley, Scott Eliasof, Andrew J. Clark, Marwan Fakih, Vincent Chung, James Lin, Edward Graeme Garmey, Dean Lim
Publikováno v:
Journal of Gastrointestinal Oncology. 8:962-969
Background: Camptothecin (CPT) derivatives such as irinotecan have activity in 2nd-line therapy in advanced GEC with reported response rates of 0-15%. CRLX101 is an investigational nanoparticle-drug conjugate (NDC) with a CPT payload. Preclinical evi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e41936fc957f801f729a25c78da08c4c
https://doi.org/10.21037/jgo.2017.08.10
https://doi.org/10.21037/jgo.2017.08.10